Approved accessible "tagraxofusp-erzs-injection"

Tagraxofusp-erzs injection is approved by USFDA for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients aged above 2 years. There is a chance for liver damage. Patients should be monitored for liver enzymes regularly. Most common side effects reported with tagraxofusp-erzs are capillary leak syndrome, nausea, fatigue, peripheral edema, pyrexia(high temperature) and weight gain. Most common laboratory abnormalities are decreased albumin, platelets, hemoglobin, calcium, sodium, and increased glucose.

Elzonris is a medicine used to treat adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a type of blood cancer which can affect many organs including the skin, the bone marrow (the spongy tissue inside the large bones) and the lymph nodes. BPDCN is rare, and Elzonris was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 11 November 2015.

How can 1 go about obtaining tagraxofusp-erzs-injection?

To access tagraxofusp-erzs-injection sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN's Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj)

Elzonris (tagraxofusp-erzs injection) for intravenous use Initial U.S. Approval: 2018